Respiratory infections are among the leading causes of illness and death in the elderly, driven by immune aging, chronic ...

Chronic lung infections pose a disproportionate threat to older adults, yet the biological mechanisms behind age-specific ...

Control of PRRSV, PCV2, IAV through vaccination, management and disease elimination most effective way of preventing the ...

“Patients with pulmonary edema generally describe breathlessness. Sometimes they feel like they are suffocating or breathing ...

The latest announcement is out from Savara ( (SVRA) ).

PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare ...

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) said it has resubmitted its biologics license application for MOLBREEVI to the U.S. Food and Drug Administration, a key regulatory step toward approval ...

SINGAPORE – A total of 143 people are being investigated by the police for their suspected involvement in scams where victims lost more than $3.82 million. This follows a two-week operation by ...

Investing.com - Savara (NASDAQ:SVRA) stock advanced after Guggenheim reiterated its Buy rating and $11.00 price target following the company’s resubmission of its Biologics License Application (BLA) ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced today that it has resubmitted the MOLBREEVI BLA to the FDA, with ...

-- The BLA was Resubmitted with FUJIFILM Biotechnologies (Fujifilm) as the Drug Substance Manufacturer and Priority Review was Requested -- MOLBREEVI was granted Fast Track and Breakthrough Therapy ...

LANGHORNE, Pa. - Savara Inc. (NASDAQ:SVRA) announced Monday it has resubmitted its Biologics License Application (BLA) for MOLBREEVI to the U.S. Food and Drug Administration with FUJIFILM ...